While it has not been used as a single agent in HPV+OPSCC, evidence suggests that preclinical co-administration of STING activators may improve tumour responses to ICIs [221] or cetuximab [222] in HPV+OSPCC cells. The gene discussed is STING1; the disease is neoplasm.